Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Mol Genet Metab ; 127(4): 346-354, 2019 08.
Artigo em Espanhol | MEDLINE | ID: mdl-31303277

RESUMO

INTRODUCTION: Morbidity and mortality in adults with late-onset Pompe disease (LOPD) results primarily from persistent progressive respiratory muscle weakness despite treatment with enzyme replacement therapy (ERT). To address this need, we have developed a 12-week respiratory muscle training (RMT) program that provides calibrated, individualized, and progressive pressure-threshold resistance against inspiration and expiration. Our previous results suggest that our RMT regimen is safe, well-tolerated, and results in large increases in respiratory muscle strength. We now conduct an exploratory double-blind, randomized control trial (RCT) to determine: 1) utility and feasibility of sham-RMT as a control condition, 2) the clinically meaningful outcome measures for inclusion in a future efficacy trial. This manuscript provides comprehensive information regarding the design and methods used in our trial and will aid in the reporting and interpretation of our future findings. METHODS: Twenty-eight adults with LOPD will be randomized (1:1) in blocks of 4 to RMT (treatment) or sham-RMT (control). Assessments will be conducted at pretest, posttest, 3-months detraining, and 6-months detraining. The primary outcome is maximum inspiratory pressure (MIP). Secondary outcomes include maximum expiratory pressure (MEP), 6-min walk test (6MWT), Gait, Stairs, Gowers, and Chair test (GSGC), peak cough flow (PCF), and patient-reported life activity/social participation (Rasch-built Pompe-specific Activity scale [R-Pact]). Exploratory outcomes include quantitative measures from polysomnography; patient reported measures of fatigue, daytime sleepiness, and sleep quality; and ultrasound measures of diaphragm thickness. This research will use a novel tool to provide automated data collection and user feedback, and improve control over dose. ETHICS AND DISSEMINATION: The results of this clinical trial will be promptly analyzed and submitted for publication. Results will also be made available on clinicaltrials.gov. ClinicalTrials.gov: NCT02801539, R21AR069880.


Assuntos
Exercícios Respiratórios , Doença de Depósito de Glicogênio Tipo II/terapia , Método Duplo-Cego , Humanos , Qualidade de Vida , Ensaios Clínicos Controlados Aleatórios como Assunto , Testes de Função Respiratória , Músculos Respiratórios/fisiologia , Adulto Jovem
2.
J Clin Med ; 10(16)2021 Aug 16.
Artigo em Inglês | MEDLINE | ID: mdl-34441913

RESUMO

Bulbar and respiratory weakness occur commonly in children with Pompe disease and frequently lead to dysarthria. However, changes in vocal quality associated with this motor speech disorder are poorly described. The goal of this study was to characterize the vocal function of children with Pompe disease using auditory-perceptual and physiologic/acoustic methods. High-quality voice recordings were collected from 21 children with Pompe disease. The Grade, Roughness, Breathiness, Asthenia, and Strain (GRBAS) scale was used to assess voice quality and ratings were compared to physiologic/acoustic measurements collected during sustained phonation tasks, reading of a standard passage, and repetition of a short phrase at maximal volume. Based on ratings of grade, dysphonia was present in 90% of participants and was most commonly rated as mild or moderate in severity. Duration of sustained phonation tasks was reduced and shimmer was increased in comparison to published reference values for children without dysphonia. Specific measures of loudness were found to have statistically significant relationships with perceptual ratings of grade, breathiness, asthenia, and strain. Our data suggest that dysphonia is common in children with Pompe disease and primarily reflects impairments in respiratory and laryngeal function; however, the primary cause of dysphonia remains unclear. Future studies should seek to quantify the relative contribution of deficits in individual speech subsystems on voice quality and motor speech performance more broadly.

3.
Neuromuscul Disord ; 30(11): 904-914, 2020 11.
Artigo em Inglês | MEDLINE | ID: mdl-33127291

RESUMO

To address progressive respiratory muscle weakness in late-onset Pompe disease (LOPD), we developed a 12-week respiratory muscle training (RMT) program. In this exploratory, double-blind, randomized control trial, 22 adults with LOPD were randomized to RMT or sham-RMT. The primary outcome was maximum inspiratory pressure (MIP). Secondary and exploratory outcomes included maximum expiratory pressure (MEP), peak cough flow, diaphragm ultrasound, polysomnography, patient-reported outcomes, and measures of gross motor function. MIP increased 7.6 cmH2O (15.9) in the treatment group and 2.7 cmH2O (7.6) in the control group (P = 0.4670). MEP increased 14.0 cmH2O (25.9) in the treatment group and 0.0 cmH2O (12.0) in the control group (P = 0.1854). The only statistically significant differences in secondary/exploratory outcomes were improvements in time to climb 4 steps (P = 0.0346) and daytime sleepiness (P = 0.0160). The magnitude of changes in MIP and MEP in the treatment group were consistent with our pilot findings but did not achieve statistical significance in comparison to controls. Explanations for this include inadequate power and baseline differences in subject characteristics between groups. Additionally, control group subjects appeared to exhibit an active response to sham-RMT and therefore sham-RMT may not be an optimal control condition for RMT in LOPD.


Assuntos
Exercícios Respiratórios/métodos , Doença de Depósito de Glicogênio Tipo II/fisiopatologia , Músculos Respiratórios/fisiopatologia , Adulto , Idoso , Diafragma/fisiopatologia , Método Duplo-Cego , Feminino , Humanos , Inalação/fisiologia , Masculino , Pessoa de Meia-Idade , Debilidade Muscular/fisiopatologia , Testes de Função Respiratória , Ultrassonografia
4.
J Cell Biol ; 156(3): 567-77, 2002 Feb 04.
Artigo em Inglês | MEDLINE | ID: mdl-11827985

RESUMO

We have analyzed mice that lack both the myelin-associated glycoprotein (MAG) and the myelin galactolipids, two glial components implicated in mediating axo-glial interactions during the myelination process. The single-mutant mice produce abnormal myelin containing similar ultrastructural abnormalities, suggesting that these molecules may play an overlapping role in myelin formation. Furthermore, the absence of the galactolipids results in a disruption in paranodal axo-glial interactions, and we show here that similar, albeit less severe, abnormalities exist in the developing MAG mutant. In the double-mutant mice, maintenance of axo-glial adhesion is significantly more affected than in the single mutants, supporting the overlapping function hypothesis. We also show that independently of MAG, galactolipids, and paranodal junctional components, immature nodes of Ranvier form normally, but rapidly destabilize in their absence. These data indicate that distinct molecular mechanisms are responsible for the formation and maintenance of axo-glial interactions.


Assuntos
Comunicação Celular/genética , Glicolipídeos/deficiência , Bainha de Mielina/metabolismo , Glicoproteína Associada a Mielina/deficiência , Malformações do Sistema Nervoso/fisiopatologia , Sistema Nervoso/metabolismo , Neuroglia/metabolismo , Animais , Axônios/metabolismo , Axônios/patologia , Axônios/ultraestrutura , Diferenciação Celular/genética , Feminino , Galactolipídeos , Glicolipídeos/genética , Imuno-Histoquímica , Masculino , Camundongos , Camundongos Knockout , Camundongos Mutantes Neurológicos/anormalidades , Camundongos Mutantes Neurológicos/metabolismo , Microscopia Eletrônica , Mutação/fisiologia , Bainha de Mielina/patologia , Bainha de Mielina/ultraestrutura , Glicoproteína Associada a Mielina/genética , Sistema Nervoso/patologia , Malformações do Sistema Nervoso/genética , Malformações do Sistema Nervoso/patologia , Neuroglia/patologia , Neuroglia/ultraestrutura , Fenótipo , Nós Neurofibrosos/metabolismo , Nós Neurofibrosos/patologia , Nós Neurofibrosos/ultraestrutura , Nervo Isquiático/anormalidades , Nervo Isquiático/patologia , Nervo Isquiático/ultraestrutura , Medula Espinal/anormalidades , Medula Espinal/patologia , Medula Espinal/ultraestrutura
5.
Neurotoxicology ; 27(5): 846-51, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16860869

RESUMO

In a pilot developmental neurotoxicity study, a protocol was designed to utilize three-dimensional magnetic resonance (MR) images for linear and volumetric measurements of the developing rat brain. MR imaging, because of its non-destructive nature, provides a complement to traditional optical microscopy. Sprague-Dawley dams received 0, 1.25, 4.0 or 7.5mg/kg methylazoxymethanol acetate (MAM) by intraperitoneal injection during gestation days 13-15. At postnatal days (PND) 23 and 60, brains from representative male and female rats from two dams in each dose group were fixed with 10% neutral buffered formalin by transcardial perfusion for in situ MR imaging. A 7T small animal magnet system was used to obtain isotropic images at 100 microm resolution for PND 23 and 150 microm resolution for PND 60. Data from a rapid screening method based on midpoint MR slices of whole brain, cerebrum, cerebellum, and hippocampus showed a dose-related decreased volume of whole brain, cerebrum, and hippocampus in treated rats. Subsequent volumetric estimates using the Cavalieri method confirmed these findings. The brains were subsequently removed and processed for conventional histologic examination of hematoxylin and eosin-stained sections. It is concluded that MR imaging in rat developmental neurotoxicity studies offers the advantages of in situ volumetric measurements of brain structures while preserving the samples for conventional optical microscopy.


Assuntos
Hipocampo/patologia , Imageamento por Ressonância Magnética/métodos , Síndromes Neurotóxicas/diagnóstico , Animais , Animais Recém-Nascidos , Peso Corporal/efeitos dos fármacos , Relação Dose-Resposta a Droga , Feminino , Hipocampo/efeitos dos fármacos , Hipocampo/crescimento & desenvolvimento , Processamento de Imagem Assistida por Computador/métodos , Masculino , Acetato de Metilazoximetanol/toxicidade , Síndromes Neurotóxicas/etiologia , Tamanho do Órgão/efeitos dos fármacos , Projetos Piloto , Gravidez , Inibidores da Síntese de Proteínas/toxicidade , Ratos , Ratos Sprague-Dawley
6.
Biochim Biophys Acta ; 1573(3): 406-13, 2002 Dec 19.
Artigo em Inglês | MEDLINE | ID: mdl-12417425

RESUMO

Myelination is a developmentally regulated process whereby myelinating glial cells elaborate large quantities of a specialized plasma membrane that ensheaths axons. The myelin sheath contains an unusual lipid composition in that the glycolipid galactosylceramide (GalC) and its sulfated form sulfatide constitute a large proportion of the total lipid mass. These glycolipids have been implicated in a range of developmental processes such as cell differentiation and myelination initiation, but analyses of mice lacking UDP-galactose:ceramide galactosyltransferase (CGT), the enzyme required for myelin galactolipid synthesis, have more recently demonstrated that the galactolipids more subtly regulate myelin formation. The CGT mutants display a delay in myelin maturation and axo-glial interactions develop abnormally. By interbreeding the CGT mutants with mice that lack myelin-associated glycoprotein, it has been shown that these specialized myelin lipids and proteins act in concert to promote axo-glial adhesion during myelinogenesis. The analysis of the CGT mutants is helping to clarify the roles myelin galactolipids play in regulating the development, and ultimately the function of the myelin sheath.


Assuntos
Axônios/fisiologia , Galactolipídeos/metabolismo , Bainha de Mielina/metabolismo , Neuroglia/fisiologia , Animais , Sistema Nervoso Central/enzimologia , Galactosiltransferases/metabolismo , Gangliosídeo Galactosiltransferase , Junções Intercelulares/metabolismo , Junções Intercelulares/fisiologia , Glicoproteína Associada a Mielina/metabolismo , Neurônios/metabolismo , Neurônios/fisiologia , Oligodendroglia/metabolismo , Oligodendroglia/fisiologia
7.
Neuron Glia Biol ; 1(3): 179-92, 2004 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18634596

RESUMO

To ensure rapid and efficient impulse conduction, myelinated axons establish and maintain specific protein domains. For instance, sodium (Na+) channels accumulate in the node of Ranvier; potassium (K+) channels aggregate in the juxtaparanode and neurexin/caspr/paranodin clusters in the paranode. Our understanding of the mechanisms that control the initial clustering of these proteins is limited and less is known about domain maintenance. Correlative data indicate that myelin formation and/or mature myelin-forming cells mediate formation of all three domains. Here, we test whether myelin is required for maintaining Na+ channel domains in the nodal gap by employing two demyelinating murine models: (1) cuprizone ingestion, which induces complete demyelination through oligodendrocyte toxicity; and (2) ceramide galactosyltransferase deficient mice, which undergo spontaneous adult-onset demyelination without oligodendrocyte death. Our data indicate that the myelin sheath is essential for long-term maintenance of sodium channel domains; however, oligodendrocytes, independent of myelin, provide a partial protective influence on the maintenance of nodal Na+ channel clusters. Thus, we propose that multiple mechanisms regulate the maintenance of nodal protein organization. Finally, we present evidence that following the loss of Na+ channel clusters the chronological progression of expression and reclustering of Na+ channel isoforms during the course of CNS remyelination recapitulates development.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA